Shenzhuo formulation ameliorates diabetic nephropathy by regulating cytochrome P450-mediated arachidonic acid metabolism

doi:10.4239/wjd.v16.i5.103511

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 16, Issue 5

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Supplementary Materials of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (19)

All Articles published online

The chart showing PDF series, HTML series, Figures (1-6) series.

Item

Count

PDF

HTML

Figures (1-6)

Sum=17

May 15, 2025 (publication date) through Apr 25, 2025

Times Cited of This Article

Times Cited (0)

Journal Information of This Article

Publication Name

World Journal of Diabetes

ISSN

1948-9358

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Basic Study

World J Diabetes. May 15, 2025; 16(5): 103511
Published online May 15, 2025. doi: 10.4239/wjd.v16.i5.103511

Shenzhuo formulation ameliorates diabetic nephropathy by regulating cytochrome P450-mediated arachidonic acid metabolism

Zhong-Yong Zhang, Yu-Ming Wang, Ning Wang, Yuan-Song Wang, Hui Zhang, Duo Wang, Li-Xin Wang, Huan-Tian Cui, Wei-Bo Wen, Shu-Quan Lv, Yong-Jun Cao

Zhong-Yong Zhang, Yuan-Song Wang, Hui Zhang, Li-Xin Wang, Shu-Quan Lv, Department of Endocrinology, Cangzhou Hospital of Integrated Traditional Chinese Medicine and Western Medicine of Hebei Province Affiliated to Hebei University of Chinese Medicine, Cangzhou 061012, Hebei Province, China

Yu-Ming Wang, College of Integrative Chinese and Western Medicine, Tianjin University of Traditional Chinese Medicine, Tianjin 301617, China

Ning Wang, Huan-Tian Cui, Wei-Bo Wen, The First School of Clinical Medicine, Yunnan University of Chinese Medicine, Kunming 650500, Yunnan Province, China

Duo Wang, North China University of Science and Technology, Tangshan 063000, Hebei Province, China

Yong-Jun Cao, Department of Endocrinology, Nantong Affiliated Hospital, Nanjing University of Traditional Chinese Medicine, Nantong 226000, Jiangsu Province, China

Co-first authors: Zhong-Yong Zhang and Yu-Ming Wang.

Co-corresponding authors: Shu-Quan Lv and Yong-Jun Cao.

Author contributions: Zhang ZY and Wang YM contributed to writing-original draft, investigation; Cao YJ contributed to investigation; Wang YM and Wang N contributed to investigation, validation, data curation; Wang YS and Wang LX contributed to investigation, validation; Zhang H, Wang D contributed to investigation, formal analysis; Cui HT and Wen WB contributed to validation, conceptualization; Lv SQ contributed to writing - review & editing; All authors have read and approved the final manuscript. Lv SQ and Cao YJ contributed to conceptualization. Zhang ZY and Cao YJ contributed to funding acquisition. Lv SQ and Cao YJ have made crucial and indispensable contributions towards the completion of the project and thus qualified as the co-corresponding authors of the paper.

Supported by the Natural Science Foundation of Hebei Province Beijing-Tianjin-Hebei Basic Research Special Program, No. H2020110287; Key Laboratory for Diabetic Kidney Disease Syndrome and Treatment of the Traditional Chinese Medicine Administration of Hebei Province, No. 7 [2024]; Yuansong Wang National Famous Traditional Chinese Medicine Expert Heritage Studio, No. 3 [2024]; Hebei Key Laboratory of Integrated Traditional Chinese and Western Medicine for Diabetes and Its Complications, No. SZX2020015; and Jiangsu Province Chinese Medicine Science and Technology Development Program Project, No. YB2020065.

Institutional animal care and use committee statement: All experimental procedures followed the Guidelines for Animal Ethics and received approval from Cangzhou Hospital of Integrated Traditional Chinese Medicine and Western Medicine of Hebei Province (Approval Number: CZX2024-KY-129).

Conflict-of-interest statement: The authors report no relevant conflicts of interest for this article.

ARRIVE guidelines statement: The authors have read the ARRIVE guidelines, and the manuscript was prepared and revised according to the ARRIVE guidelines.

Data sharing statement: The original contributions presented in the study are included in the article/Supplementary material. Further inquiries can be directed to the corresponding authors at czlvshuquan@163.com.

Open Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/

Corresponding author: Shu-Quan Lv, PhD, Chief Physician, Department of Endocrinology, Cangzhou Hospital of Integrated Traditional Chinese Medicine and Western Medicine of Hebei Province Affiliated to Hebei University of Chinese Medicine, No. 5 Xianghai Road, High-tech Zone, Cangzhou 061012, Hebei Province, China. czlvshuquan@163.com

Received: November 28, 2024
Revised: December 31, 2024
Accepted: February 17, 2025
Published online: May 15, 2025
Processing time: 154 Days and 23.7 Hours

Core Tip

Core Tip: This study aimed to evaluate the therapeutic impact of Shenzhuo formulation (SZF) on a diabetic nephropathy (DN) mouse model and to examine its potential molecular mechanisms using transcriptomic and metabolomic approaches. The findings of this research substantiated the significant potential of SZF in ameliorating renal injury in DN mice. The primary pathway through which SZF mitigates renal injury appears to be the modulation of cytochrome P450-mediated AA metabolism, which contributes to its anti-inflammatory and antioxidant effects.